Back to Results

Gait Analysis in MPS IVA

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT01920828

Condition

MPS IVA, Morquio Syndrome

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

The purpose of this study is to learn about gait (walking) characteristics in MPS IVA and possible changes in gait with enzyme replacement therapy.

Eligibility Criteria

Birth Sex

All

Age

From 1 Year

Healthy Volunteers

No

Study Type:

Observational

Number of Participants:

10

Study Started:

2013-08

Study Updated:

2019-10-17

Trial Locations

  • Oregon Health and Science University

    Portland, Oregon, United States

Inclusion Criteria

-Diagnosis of MPS IVA

Exclusion Criteria

Non-ambulatory

  • Previous enrolled in clinical trial BMN-11

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us